Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.60 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.42 |
| ▸ | CXCR5 | P32302 | 7/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561333 | 0.91 | LPAR1 (0.68) | LPAR1GPR132CXCR5 | |
| SCHEMBL1560963 | 0.91 | LPAR1 (0.57) | LPAR1GPR132CXCR5 | |
| SCHEMBL1561271 | 0.86 | LPAR1 (0.73) | LPAR1GPR132CXCR5 | |
| SCHEMBL1561378 | 0.84 | LPAR1 (0.67) | LPAR1GPR132CXCR5F10 | |
| SCHEMBL1560554 | 0.81 | LPAR1 (0.60) | LPAR1GPR132CXCR5F10ERAP1 | |
| SCHEMBL1560511 | 0.80 | LPAR1 (0.60) | LPAR1CXCR5 | |
| SCHEMBL1809260 | 0.80 | LPAR1 (0.61) | LPAR1GPR132 | |
| SCHEMBL1809808 | 0.80 | LPAR1 (0.61) | LPAR1GPR132 | |
| SCHEMBL18832667 | 0.79 | LPAR1 (0.53) | LPAR1GPR132F10 | |
| SCHEMBL1561628 | 0.79 | LPAR1 (0.58) | LPAR1CXCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | LPAR1 6/4885GPR132 539/4885CXCR5 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.